16.35USDMkt Cap: 859.45M USDP/E: —Last update: 2026-05-22
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap859.45M USD
Enterprise Value354.44M USD
Revenue (TTM)59.00K USD
Gross Profit59.00K USD
Net Income (TTM)-78.26M USD
Revenue/Share0.0040 USD
Last Price16.35 USD
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees33
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.78
PEG—
EV/EBITDA-4.88
EV/Revenue6007.49
P/S14789.64
P/B3.70
EPS (TTM)-5.57
EPS (Forward)-2.87
52W Range
16.0233% of range17.01
52W High17.01 USD
52W Low16.02 USD
Profitability
Gross Margin100.00%
Oper. Margin-33461.02%
EBITDA Margin0.00%
Profit Margin-132642.37%
ROE-94.23%
ROA-67.20%
Growth
Revenue Growth-69.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-51.46M USD
CapEx (TTM)—
FCF Margin-29259.53%
FCF Yield-2.01%
Net Debt-97.91M USD
Net Debt/EBITDA1.35
Balance Sheet
Debt/Equity0.00
Current Ratio8.14
Quick Ratio7.60
Book Value/Sh4.486 USD
Cash/Share4.315 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:240
Split DateDec 29, 2023
Analyst Consensus
Rating1.2 (Strong Buy)
Target (Mean)46.18 USD
Target Range34.00 USD – 60.00 USD
# Analysts11
Ownership
Shares Out.52.57M
Float20.16M
Insiders1.61%
Institutions60.62%
Short Interest
Short Ratio7.3d
Short % Float21.53%
Short % Out.21.46%
Shares Short5.73M
Short (prev mo.)5.54M
Technical
SMA 5015.61 (+4.8%)
SMA 20015.05 (+8.7%)
Beta0.79
S&P 52W Chg28.31%
Avg Vol (30d)1.31M
Avg Vol (10d)1.81M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—